EEKLIVVAF 

EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5^[1][2].

EEKLIVVAF can be recognized by CTL clone on C1RB*4402 and C1R-B*4403 cells, and (45 ng/mL and 160 ng/mL, respectively; 30 min; 20 ℃) shows the ability to compete with a standard peptide for binding to HLA-B*4402 and HLA-B*4403 molecules^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1047.24

C₅₀H₈₂N₁₀O₁₄

188818-21-5

EEKLIVVAF

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Herman J, et al. Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. Tissue Antigens. 1999 Feb;53(2):111-21.  [Content Brief]

  [2]. Herman J, et al. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics. 1996;43(6):377-83.  [Content Brief]

  [3]. Coulie PG, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7976-80.  [Content Brief]